<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1911246281
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OXIMAL 15MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MELOXICAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        9.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1055]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Dallah Health Care Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AC06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><br />□ The name of your medicine is OXIMAL. The active ingredient is Meloxicam. This belongs to a group of medicines known as<br />Non Steroidal Anti-Inflammatory agent which reduce the inflammation and pain in the joints and muscle.<br />This medicine is used for:<br />□ Short term treatment of acute attacks of osteoarthritis<br />□ Long term treatment of pain and stiffness in joint (rheumatoid arthritis) or backbone (ankylosing spondylitis).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take OXIMAL:<br />□ If you are pregnant or breastfeeding<br />□ If you are allergic to OXIMAL or any other ingredients (see section 6)<br />□ If you are allergic (hypersensitive) to aspirin or other non-steroidal anti-inflammatory medicines (NSAIDs)<br />□ If you have developed signs of asthma (wheezing), nasal polyps (nasal obstruction) along with runny nose, swelling of the skin<br />or rash when taking aspirin or other anti-inflammatory medicines.<br />□ If you have peptic ulcer (ulcer in your stomach or duodenum) or bleeding in your stomach or have had two or more episodes<br />of peptic ulcers, stomach bleeding or perforation<br />□ Have severe liver disease<br />□ Have severe kidney failure and are not receiving dialysis.<br />□ Have gastrointestinal bleeding (bleeding in the stomach or gut) or cerebrovascular bleeding (bleeding in the brain) or have a<br />bleeding disorder.<br />□ Suffer from severe uncontrolled heart failure<br />Take special care with OXIMAL:<br />□ If you use other non-steroidal anti-inflammatory medicines (NSAIDs) or any medication which may cause bleeding or ulcers in<br />the stomach.<br />□ If you have a history of gastrointestinal disease e.g. inflammation of the stomach (gastritis) or gullet(osteophgitis),ulcer,<br />ulcerative colitis, Crohn&rsquo;s disease<br />□ If you are elderly<br />□ If you have high blood pressure or any liver, kidney or heart problems.<br />□ If you have or have had bronchial asthma<br />□ If you are trying to become pregnant or undergoing investigation of fertility<br />□ If you suffer from lupus or any other disease.<br />Taking other medicines:<br />Please tell your doctor or pharmacist if you are taking or have recently taken any of the following medicine, including medicines<br />obtained without prescription.<br />□ Other non steroidal anti-inflammatory drugs e.g. aspirin, ibuprofen or naproxen □ Medicines which prevent blood clotting such<br />as warfarin □ Medicines which break down blood clots (thrombolytics) □ Corticosteroids □ Certain medicines used to treat<br />depression (SSRI) □ Any diuretics (water tablet) medicine e.g. bendroflumethiazide, furosemide or acetazolamide □ ACE<br />inhibitors e.g. captopril or ramipril □ Angiotensin II antagonists e.g. candesartan or losartan □ Any other drugs used to treat<br />high blood pressure (e.g. beta-blocker such as acebutolol or oxprenolol) □ Cyclosporine □ Intra-uterine contraceptive device<br />(IUD), commonly called the coil<br />□ Lithium which used to treat depression □ Methotrexate, used to treat some types of cancer or psoriasis or rheumatoid<br />arthritis<br />□ Colestyramine, used to reduce cholesterol □ Cardiac glycoside (e.g. digoxin) □ Certain antibiotics □ Zidovudine (anti HIV<br />medicine)<br />□ Mifepristone (a type of steroid) □ Tacrolimus.<br />Tell your doctor about any other medicines you are taking even those obtained without prescription.<br />Taking OXIMAL with food and drink:<br />□ Take OXIMAL with or after food<br />□ Swallow with water<br />Pregnancy and breastfeeding:<br />Pregnancy: □ OXIMAL should not be used during pregnancy □ If you are planning to become pregnant, if you think or know<br />you are pregnant you should talk to your doctor for advice □ OXIMAL may make it more difficult to become pregnant. You<br />should inform your doctor if you are planning to become pregnant or if you have problems becoming pregnant<br />Breast-feeding: OXIMAL should not be given to breast-feeding mothers.<br />Driving and using machines: These tablets may make you feel light headed, dizzy or drowsy and may cause blurred vision. If<br />they affect you in this way DO NOT drive or operate machinery.<br />Important information about one of the ingredients of OXIMAL: These tablets contain lactose. If you have been told by your<br />doctor that you have intolerance to some sugar. Contact your doctor before taking this medicinal product.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow your doctor&rsquo;s instructions about when and how to take your medicine and always read the label.<br />Warnings:<br />□ Medicines such as OXIMAL may be associated with a small increased risk of heart attack (&lsquo;myocardial infarction&rsquo;) or stroke.<br />□ Any risk is more likely with high doses and prolonged treatment. Do not exceed the recommended dose or duration of<br />treatment.<br />□ If you have heart problems, previous stroke or think that you might be at risk of these conditions (for example if you have high<br />blood pressure, diabetes or high cholesterol or are smoker) you should discuss your treatment with your doctor or pharmacist.<br />Adult and adolescents (over the age of 16):<br />□ Depending on the type of condition you have, the usual recommended dosage is 7.5 mg or 15 mg take once daily with food.<br />□ If you need to take two tablets they must be taken together as a single dose.<br />Infants and children:<br />□ OXIMAL tablets should not be used in children under the age of 16.<br />Acute attack of osteoarthritis:<br />□ The usual dose is 7.5 mg a day. Your doctor may increase your dose to 15 mg a day if necessary.<br />Pain and stiffness in joint (Rheumatoid Arthritis) or backbone (Anklosing spondylitis):<br />□ The usual dose is 15 mg a day .your doctor may reduce your dose to 7.5 mg a day if necessary. Elderly patients and Patients<br />with increased risk of side effects:<br />□ The recommended dose for long term treatment of pain and stiffness in joint and backbone in the elderly is 7.5 mg a day.<br />□ Patient with increased risk of side effects should start treatment with 7.5 mg a day.<br />Patients with kidney problems:<br />□ OXIMAL tablets are not recommended for use in patients with severe kidney failure who are not receiving dialysis.<br />□ The maximum recommended dose for treatment in dialysis patients with severe kidney failure is 7.5 mg a day<br />□ Patients with mild to moderate kidney problems should use the normal dose.<br />Do not exceed the recommended maximum dose of 15 mg daily.<br />If after several days taking OXIMAL you feel no improvement talk to your doctor.<br />If you take more OXIMAL than you should:<br />If you take more tablets than you should tell your doctor immediately or go to the nearest hospital. Bring this leaflet or the carton<br />pack with you.<br />Symptoms of overdose include lack of energy, drowsiness, nausea, vomiting and stomach pain.<br />If you forget to take OXIMAL:<br />Take your tablet as soon as you remember. If it is almost time for your next dose, wait until that is due and continue as normal.<br />Do not take a double dose to make up for the forgotten dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Stop taking OXIMAL and consult a doctor or your nearest hospital immediately if you notice:<br />Any allergic (hypersensitivity) reactions, which may appear in the form of:<br />□ skin reactions, such as itching (pruritus), blistering or peeling of the skin, which can be potentially life-threatening skin rashes<br />(Stevens-Johnson syndrome, toxic epidermal necrolysis), lesions of soft tissues (mucosal lesions) or erythema multiforme.<br />Erythema multiforme is a serious allergic skin reaction causing spots, red welts or purple or blistered areas. It can also affect the<br />mouth, eyes and other moist body surfaces.<br />□ Swelling of skin or mucosa, such as swelling around the eyes, face and lips, mouth or throat, possibly making breathing<br />difficult, swollen ankles or legs (oedema of the lower limbs)<br />□ Shortness of breath or asthma attack<br />□ Inflammation of the liver (hepatitis). This can cause symptoms such as: - Yellowing of the skin or the eyeballs (jaundice)<br />- Pain in the abdomen - Loss of appetite<br />Any side effects of the digestive tract, especially:<br />□ Bleeding (causing tar-coloured stools)<br />□ Ulceration of your digestive tract (causing abdominal pain)<br />Bleeding of the digestive tract (gastrointestinal bleeding), formation of ulcers or formation of a hole in the digestive tract<br />(perforation) may sometimes be severe and potentially fatal, especially in elderly.<br />If you have previously suffered from any symptoms of the digestive tract due to long term use of NSAIDs, seek medical advice<br />immediately, especially if you are elderly. Your doctor may monitor your progress whilst on treatment.<br />If affected by visual disturbances do not drive or operate machinery.<br />General side effects of non-steroidal antiinflammatory medicines (NSAIDs):<br />The use of some non-steroidal anti-inflammatory drugs (NSAIDs) may be associated with a small increased risk of occlusion of<br />arterial vessels (arterial thrombotic events), e.g. heart attack (myocardial infarction) or stroke (apoplexy), particularly at high<br />doses and in long term treatment.<br />Fluid retention (oedema), high blood pressure (hypertension) and heart failure (cardiac failure) have been reported in<br />association with NSAID treatment.<br />The most commonly-observed side effects affect the digestive tract (gastrointestinal events): □ Ulcers of the stomach and upper<br />part of the small bowels (peptic/gastroduodenal ulcers) □ A hole in the wall of the bowels (perforation) or bleeding of the<br />digestive tract (sometimes fatal, particularly in the elderly)<br />The following side effects have been reported after NSAID administration: □ Feeling sick (nausea) and being sick (vomiting)<br />□ Loose stools (diarrhoea) □ Flatulence □ Constipation □ Indigestion (dyspepsia) □ Abdominal pain □ Tar-coloured stool due to<br />bleeding in the digestive tract (melaena) □ Vomiting of blood (haematemesis) □ Inflammation with building of ulcers in the<br />mouth (ulcerative stomatitis) □ Worsening of inflammation of the digestive tract (e.g. exacerbation of colitis or Crohn&rsquo;s disease)<br />Less frequently, inflammation of the stomach (gastritis) has been observed.<br />Side effects of Meloxicam - the active substance of OXIMAL:<br />Very common: affects more than 1 user in 10: □ Gastrointestinal adverse events such as indigestion (dyspepsia), feeling sick<br />(nausea) and being sick (vomiting), abdominal pain, constipation, flatulence, loose stools (diarrhoea)<br />Common: affects 1 to 10 users in 100: □ Headache<br />Uncommon: affects 1 to 10 users in 1,000: □ Dizziness (light-headedness) □ A feeling of dizziness or spinning (vertigo)<br />□ Somnolence (drowsiness) □ Anaemia (reduction of the concentration of the red blood pigment haemoglobin) □ Increase in<br />blood pressure (hypertension) □ Flushing (temporary redness of the face and neck) □ Sodium and water retention □ Increased<br />potassium levels (hyperkalaemia). This can lead to symptoms such as: - changes to your heartbeat (arrythmias) - palpitations<br />(when you feel your heartbeat more than usual) - muscle weakness<br />□ Eructation □ Inflammation of the stomach (gastritis) □ Bleeding of the digestive tract □ Inflammation of the mouth (stomatitis)<br />□ Immediate allergic (hypersensitivity) reactions □ Itching (pruritus) □ Skin rash □ Swelling caused by fluid retention (oedema)including swollen ankles/legs (oedema of the lower limbs) □ Sudden skin or mucosal swelling, such as swelling<br />around the eyes, face, lips, mouth or throat, possibly making breathing difficult (angioneurotic oedema) □ Momentary<br />disturbance of liver function tests (e.g. raised liver enzymes like transaminases or an increase of the bile pigment bilirubin). Your<br />doctor can detect these using a blood test. □ Disturbance of laboratory tests investigating kidney (renal) function (e.g. raised<br />creatinine or urea)<br />Rare: affects 1 to 10 users in 10,000: □ Mood disorders □ Nightmares □ Abnormal blood count, including: - abnormal differential<br />blood count - decreased number of white blood cells (leucocytopenia) - decreased number of blood platelets<br />(thrombocytopenia) These side effects may lead to increased risk of infection and symptoms such as bruising or nosebleeds.<br />□ Ringing in the ear (tinnitus) □ Feeling your heartbeat (palpitations) □ Ulcers of the stomach or upper part of the small bowels<br />(peptic/gastroduodenal ulcers) □ Inflammation of the gullet (oesophagitis) □ Onset of asthma attacks (seen in people who are<br />allergic to aspirin or other NSAIDs) □ Severe blistering of the skin or peeling (Stevens Johnson syndrome and toxic epidermal<br />necrolysis) □ Nettle rash (urticaria) □ Visual disturbances including: - blurred vision - conjunctivitis (inflammation of the eyeball<br />or eyelids) □ Inflammation of the large bowel (colitis)<br />Very rare: affects less than 1 user in 10,000: □ Blistering reactions of the skin (bullous reactions) and erythema multiforme.<br />Erythema multiforme is a serious allergic skin reaction causing spots, red welts or purple or blistered areas. It can also affect<br />the mouth, eyes and other moist body surfaces □ Inflammation of the liver (hepatitis). This can cause symptoms such as:<br />- yellowing of the skin or the eyeballs (jaundice) - pain of the abdomen - loss of appetite □ Acute failure of the kidneys (renal<br />failure) in particular in patients with risk factors such as heart disease, diabetes or kidney disease □ A hole in the wall of the<br />bowels (perforation)<br />Not known: frequency can not be estimated from the available data:<br />□ Confusion □ Disorientation □ Shortness of breath and skin reactions (anaphylactic/anaphylactoid reactions) rashes caused<br />by exposure to sunlight (photosensitivity reactions) □ Heart failure (cardiac failure) has been reported in association with NSAID<br />treatment □ Complete loss of specific types of white blood cells (agranulocytosis), especially in patients who take OXIMAL<br />together with other drugs that are potentially inhibitory, depressant or destructive to a component of the bone marrow<br />(myelotoxic drugs). This can cause: - sudden fever - sore throat - infections<br />Side effects caused by non-steroidal antiinflammatory medicines (NSAIDs), but not yet seen after taking Meloxicam<br />Changes to the kidney structure resulting in acute kidney failure:<br />□ Very rare cases of kidney inflammation (interstitial nephritis) □ Death of some of the cells within the kidney (acute tubular or<br />papillary necrosis) □ Protein in the urine (nephrotic syndrome with proteinuria)<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />□ Do not store above 30 &deg;C.<br />□ Do not use OXIMAL after the expiry date which is stated on the carton and on the blister, after (EXP). Date<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no<br />longer required. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Meloxicam. Each tablet contains 7.5mg and 15mg, respectively, of Meloxicam.<br />The other ingredients are: Lactose, Microcrystalline cellulose, Crospovidone, Sodium Citrate and Magnesium Stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                7.5 mg tablets are light yellow circular flat face bevelled edge embossed with “OM 7.5” on one side, and plain on the other
side.
□ 15 mg tablets are light yellow scored circular flat face bevelled edge embossed with “OM 15” on one side and plain on the
other side
□ Boxes of 10 blistered tablets of OXIMAL 7.5 Tablets.
□ Boxes of 30 blistered tablets of OXIMAL 7.5 Tablets.
□ Boxes of 10 blistered tablets of OXIMAL 15 Tablets.
□ Boxes of 30 blistered tablets of OXIMAL 15 Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Jordanian pharmaceutical manufacturing co.(P.L.C.|)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 September 2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>أوكسيمال هو اسم دوائك. ميلوكسيكام هو المكوّن الفعال. وهو ينتمي إلى مجموعة من الأدوية تعرف بمضادات الالتهاب غير الستيرويدية والتي تعمل على<br />تقليل ألم و التهاب المفاصل والعضلات.<br />ويستخدم هذا الدواء لعلاج:<br />النوبات الحادة من الفصال العظمي على المدى القصير. □<br />ألم و تيبس المفاصل (التهاب المفاصل الروماتويدي) أو العمود الفقري (التهاب الفقار المقسط) على المدى الطويل</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أوكسيمال:<br />إذا كنت حاملاً أو ترضعين طفلك. □<br />.( إذا كنت تعاني من حساسية (فرط التحسس) لأقراص أوكسيمال، أو أي من مكوناته الأخرى (انظر القسم ٦ □<br />إذا كنت تعاني من حساسية (فرط التحسس) لمادة الأسبرين أو لأي من مضادات الالتهاب غير الستيرويدية. □<br />إذا ظهرت لديك أعراض الربو (صفير عند التنفس)، زوائد أنفية (انسداد أنفي) مع سيلان في الأنف، تورم في الجلد أو طفح جلدي عند تناولك أسبرين أو □<br />لأي من مضادات الالتهاب غير الستيرويدية.<br />إذا كنت تعاني من قرحة هضمية (قرحة في المعدة أو الاثني عشر) أو نزيف في المعدة أو تعرضت لنوبات من القرحة الهضمية أو نزيف أو انثقاب في □<br />المعدة مرتين أو أكثر.<br />إذا كنت تعاني من التهاب وخيم في الكبد. □<br />إذا كنت تعاني من فشل كلوي وخيم من دون تلقي غسيل للكلى. □<br />إذا كنت تعاني من نزيف معوي (نزيف في المعدة أو الأمعاء) أو نزيف دماغي وعائي (نزيف في الدماغ) أو اضطرابات نزفية. □<br />إذا كنت تعاني من فشل قلبي وخيم غير مسيطر عليه. □<br />الاحتياطات عند استعمال أوكسيمال:<br />إذا كنت تستخدم أدوية أخرى من مضادات الالتهاب غير الستيرويدية أو أي أدوية يمكن أن تؤدي إلى نزيف أو قرحة في المعدة. □<br />إذا كنت تعاني مسبقاً من أمراض الجهاز الهضمي، على سبيل المثال: التهاب في المعدة، التهاب المريء، قرحة، التهاب القولون التقرحي أو مرض كرون. □<br />إذا كنت كبير في السن. □<br />إذا كنت تعاني من ارتفاع ضغط الدم أو أي مشاكل في الكبد أو الكلى أو القلب. □<br />إذا كنت تعاني أو عانيت سابقاً من الربو القصبي. □<br />إذا كنت تخططين لتصبحي حاملاً أو تقومين بعمل فحوصات للتأكد من الخصوبة. □<br />إذا كنت تعاني من مرض الذئبة أو أي مرض آخر. □<br />تناول أدوية أخرى:<br />الرجاء إخبار الطبيب أو الصيدلاني إذا كنت تأخذ أو أخذت مؤخراً أي من الأدوية التالية، بما في ذلك الأدوية التي تم الحصول عليها من دون وصفة طبية:<br />مضادات الالتهاب غير الستيرويدية الأخرى، على سبيل المثال : الأسبرين أو الأيبوبروفين أو نابروكسن. □<br />الأدوية التي تمنع تخثر الدم مثل الوارفارين. □<br />الأدوية التي تعمل على تحليل الخثرات الدموية (حال الخثرة). □<br />الكورتيكوستيرويد. □<br />بعض الأدوية التي تستخدم لعلاج الاكتئاب (مثبط انتقائي لاسترداد السيروتونين). □<br />أي دواء مدر للبول، على سبيل المثال: بندروفلوميثيازايد أو فوروسيمايد أو أسيتازولامايد. □<br />مثبطات الإنزيم المحول للأنجيوتنسين، على سبيل المثال : كابتوبريل أو راميبريل. □<br />مضادات الأنجيوتنسين ۲، على سبيل المثال: كانديسارتان أو لوسارتان. □<br />أي أدوية أخرى تستخدم لعلاج ارتفاع ضغط الدم (مثال:محصرات البيتا مثل أسيبيوتولول أو أوكسبرينولول). □<br />سيكلوسبورين. □<br />جهاز داخل الرحم لمنع الحمل المعروف باسم اللولب الرحمي. □<br />ليثيوم و يستخدم لعلاج الاكتئاب. □<br />الميثوتركسات و يستخدم لعلاج بعض أنواع السرطان أو الصدفية أو التهاب المفاصل الروماتويدي. □<br />كوليستيرامين و يستخدم لخفض الكولسترول. □<br />غليكوزايد قلبي (على سبيل المثال: ديجوكسين). □<br />بعض أنواع المضادات الحيوية. □<br />زيدوفودين (يستخدم لعلاج العوز المناعي البشري). □<br />ميفبريستون (نوع من الستيرويد). □<br />تاكروليموس. □<br />أخبر طبيبك عن أي دواء تتناوله حتى الأدوية التي تتناولها دون وصفة طبية.<br />تناول أوكسيمال مع الطعام والمشروبات:<br />يبلع الدواء مع الماء. □ تناول أوكسيمال مع الطعام □<br />الحمل والإرضاع:<br />الحمل<br />يجب أن لا تتناولي أوكسيمال خلال فترة الحمل □<br />يجب استشارة طبيبك إذا كنت حاملاً، أو تعتقدين بأنك حاملاً أو تخططين للإنجابيمكن أن تجدي صعوبة في أن تصبحي حاملاً خلال فترة تناول أوكسيمال لذلك يجب عليك استشارة طبيبك إذا كنت تخططين لتصبحي حاملاً أو تعانين □<br />من صعوبة للحمل.<br />الإرضاع<br />لا يجب إعطاء أوكسيمال للأمهات المرضعات. □<br />قيادة السيارات واستعمال الآلات:<br />قد تجعلك هذه الأقراص تشعر بالدوار أو النعاس، و تغيم بالرؤية. لا يجب تشغيل الآلات أو قيادة السيارة إذا أثر عليك الدواء بهذه الطريقة.<br />معلومات مهمة حول بعض مكونات أوكسيمال:<br />تحتوي هذه الأقراص على لاكتوز. إذا أخبرك طبيبك من قبل بعدم تحملك لبعض السكريات، فإنه يجب عليك استشارته قبل تناولك هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>عليك اتباع تعليمات الطبيب في كيفية أخذ الدواء و عليك قراءة التعليمات دائماً.<br />تحذيرات:<br />قد تترافق بعض الأدوية التي تشبه أوكسيمال مع زيادة صغيرة لخطر الإصابة بالنوبات القلبية ( احتشاء عضلة القلب) أو السكتة الدماغية. □<br />أي من هذه المخاطر على الأرجح يكون سببها الجرعة العالية و فترات العلاج الطويلة. يجب عليك عدم تجاوز الجرعة الموصى بها و فترة العلاج □<br />المقررة.<br />إذا لديك مشاكل في عضلة القلب، سكتة دماغية سابقة أو تعتقد أنك عرضة لهذه الحالات (على سبيل المثال إذا كنت تعاني من ارتفاع ضغط الدم أو □<br />مرض السكري أو ارتفاع الكوليسترول في الدم أو كنت شخص مدخن) يجب عليك مناقشة الطبيب أو الصيدلاني بالعلاج الذي تتناوله.<br />المرضى البالغين و المراهقين (الذين تزيد أعمارهم عن ۱٦ عاماً ):<br />اعتماداً على حالتك المرضية، فإن الجرعة المعتادة الموصى بها هي ۷٫٥ ملغم أو ۱٥ ملغم مرة واحدة يومياً □<br />إذا كنت بحاجة لأخذ قرصين من الدواء يجب عليك أخذ القرصين معاً كجرعة واحدة . □<br />الرضع و الأطفال :<br />لا يجب استخدام أوكسيمال للأطفال دون عمر ۱٦ عاماً. □<br />النوبات الحادة من الفصال العظمي:<br />الجرعة المعتادة هي ۷٫٥ ملغم يومياً. يمكن أن يقوم طبيبك بزيادة الجرعة إلى ۱٥ ملغم يومياً إذا كان ذلك ضرورياً. □<br />ألم و تيبس المفصل (التهاب المفاصل الروماتويدي) أو العمود الفقري (التهاب الفقار المقسط):<br />الجرعة المعتادة هي ۱٥ ملغم يوميا. يمكن أن يقوم طبيبك بخفض الجرعة إلى ۷٫٥ ملغم يوميا إذا كان ذلك ضرورياً. □<br />المرضى كبار السن و المرضى الذين يعانون من زيادة خطر الآثار الجانبية:<br />الجرعة الموصى بها لعلاج ألم و تيبس المفاصل و العمود الفقري على المدى الطويل في المرضى كبار السن هي ۷٫٥ ملغم يومياً. □<br />يجب البدء بجرعة ۷٫٥ ملغم للمرضى الذين يعانون من زيادة خطر الآثار الجانبية. □<br />المرضى الذين يعانون من مشاكل في الكلى:<br />لا ينصح باستخدام أوكسيمال للمرضى الذين يعانون من فشل كلوي وخيم و لا يتلقون غسيل للكلى (دِيال). □<br />الجرعة القصوى الموصى بها لمرضى الفشل الكلوي الوخيم و الذين يتلقون غسيل للكلى هي ۷٫٥ ملغم في اليوم. □<br />يجب استخدام الجرعة الاعتيادية للمرضى الذين يعانون من فشل كلوي خفيف إلى معتدل. □<br />يجب عدم تجاوز الجرعة الموصى بها و هي ۱٥ ملغم يومياً.<br />تحدث إلى طبيبك إذا لم تشعر بتحسن بعد عدة أيام من تناولك أوكسيمال.<br />إذا تناولت أوكسيمال أكثر مما يجب:<br />إذا تناولت الكثير من أقراص أوكسيمال (أكثر من الجرعة المقررة) عليك التحدث إلى طبيبك أوالذهاب إلى أقرب مستشفى على الفور. أحضر معك نشرة<br />الدواء أو علبة الدواء.<br />تشمل أعراض الجرعة الزائدة نقصان في الطاقة و نعاس و غثيان وقيء وآلام في المعدة.<br />إذا نسيت تناول أوكسيمال:<br />تناول الجرعة المنسية فور تذكرك. إذا اقترب موعد الجرعة التالية، انتظر حتى ذلك الوقت وتناول الجرعة كالمعتاد ولا تتناول الجرعة المنسية. □<br />لا تحاول مضاعفة الجرعة لتعويض الجرعة التي نسيتها</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كغيره من الأدوية، فقد يسبب هذا الدواء أعراضاًً جانبية على الرغم من عدم حدوثها لجميع الأشخاص.<br />توقف عن تناول أوكسيمال وقم باستشارة طبيبك أو الذهاب إلى أقرب مستشفى مباشرة إذا لاحظت:<br />أي تفاعلات تحسسية (فرط التحسس) والتي قد تظهر على شكل:<br />تفاعلات جلدية مثل الحكة، تقرح وتقشر الجلد والذي قد يكون طفح جلدي مهدد للحياة ( متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية □<br />التسممي)، آفات الأنسجة الرخوة (آفات الغشاء المخاطي) أو حمامى عديدة الأشكال.<br />حمامى عديدة الأشكال هو تفاعل جلدي تحسسي خطير يتسبب بحدوث بقع حمراء أو أرجوانية اللون أو حدوث تقرحات جلدية. ويمكن أن يؤثر أيضاً على<br />الفم والعيون والأسطح الرطبة الأخرى الموجودة بالجسم.<br />تورم الجلد أو الغشاء المخاطي مثل، تورم حول العينين، تورم الوجه والشفاه، تورم الفم والحلق والذي قد يؤدي إلى صعوبة في التنفس، تورم الكاحلين □<br />التهاب الكبد، والذي قد يتسبب بالأعراض التالية: - اصفرار الجلد أو مقلة العين (يرقان) - ألم في البطن □ ضيق في التنفس أو نوبة ربو □ أو الساقين<br />- فقدان الشهية.<br />أي أعراض جانبية تتعلق بالسبيل الهضمي:<br />تقرح السبيل الهضمي (يتسبب بآلام في البطن) □ ( نزيف (تسبب براز لونه أسود □<br />إن حدوث نزيف وظهور تقرحات أو ثقب في السبيل الهضمي قد يشكل في بعض الأحيان خطورة ومن المحتمل أن يكون قاتلاً وخاصة لدى كبار السن.<br />إذا كنت قد عانيت مسبقاً من أعراض السبيل الهضمي نتيجة الاستخدام الطويل لمضادات الالتهاب غير الستيرويدية، فإنه يجب عليك طلب الاستشارة<br />الطبية على الفور وخاصة إذا كنت من كبار السن. قد يقوم طبيبك بمراقبة حالتك الصحية أثناء فترة علاجك.<br />لا تقوم بقيادة السيارة أو استخدام الآلات إذا حدث لك أي اضطرابات بصرية.<br />الأعراض الجانبية العامة للأدوية المضادة للالتهاب غير الستيرويدية:<br />إن استخدام بعض الأدوية المضادة للالتهاب غير الستيرويدية قد يترافق مع زيادة صغيرة لخطر الإصابة بانسداد الأوعية الشريانية (حالات الخثار<br />الشرياني) مثل، نوبة قلبية (احتشاء عضل القلب) أو سكتة دماغية وخاصة عند استخدام جرعات عالية والاستخدام لفترة طويلة.<br />تم الإبلاغ عن حدوث احتباس سوائل و ارتفاع في ضغط الدم وفشل في القلب عند المعالجة باستخدام مضادة للالتهاب غير الستيرويدية.<br />الأعراض الجانبية الأكثر شيوعاً والتي تؤثر على السبيل الهضمي:<br />قرحة المعدة وقرحة الجزء العلوي من الأمعاء الدقيقة □<br />ثقب في جدار الأمعاء أو نزف في السبيل الهضمي (أحياناً يكون قاتل لدى كبار السن) □<br />تم الإبلاغ عن الأعراض الجانبية التالية بعد تناول مضادات الالتهاب غير الستيرويدية:<br />براز لونه أسود ناجم عن نزيف في السبيل الهضمي □ ألم في البطن □ عسر الهضم □ إمساك □ انتفاخ البطن □ إسهال □ غثيان وقيء □<br />تفاقم التهابات السبيل الهضمي (تفاقم التهاب القولون أو مرض كرون) □ التهاب و تقرحات في الفم □ تقيؤ دموي □تم ملاحظة التهاب المعدة بشكل أقل تكراراً.<br />الأعراض الجانبية المتعلقة بالميلوكسيكام - المادة الفعالة للأوكسيمال:<br />الأعراض الشائعة جداً: تؤثر على أكثر من مستخدم من ۱۰ مستخدمين: الأعراض الجانبية المتعلقة بالجهاز الهضمي مثل، عسر الهضم، غثيان وقيء، ألم<br />في البطن، إمساك، انتفاخ البطن، إسهال.<br />الأعراض الشائعة: تؤثر على مستخدم واحد إلى ۱۰ من ۱۰۰ مستخدم: صداع<br />فقرالدم (انخفاض في تركيز □ نعاس □ الشعور بالدوار □ دوخة □ : الأعراض غير الشائعة: تؤثر على مستخدم واحد إلى ۱۰ من ۱۰۰۰ مستخدم<br />ارتفاع مستوى □ احتباس الماء والصوديوم □ ( احمرار (احمرار مؤقت في الوجه والرقبة □ ارتفاع ضغط الدم □ ( صبغة الهيموغلوبين في الدم<br />البوتاسيوم في الدم والذي قد يؤدي إلى ظهور الأعراض التالية: - عدم انتظام ضربات القلب - خفقان (عندما تشعر بأن دقات قلبك أكثر من المعتاد) -<br />طفح جلدي □ حكة □ تفاعلات تحسسية فورية □ التهاب الفم □ نزيف في السبيل الهضمي □ التهاب المعدة □ تجشؤ □ ضعف في العضلات<br />تورم مفاجىء في الجلد والغشاء المخاطي مثل، ، تورم حول العينين، تورم □ تورم ناجم عن تجمع السوائل، والذي يشمل تورم الكاحلين/ الساقين □<br />اضطراب مؤقت في اختبارات وظائف الكبد ( ارتفاع □ ( الوجه والشفاه، تورم الفم والحلق والذي قد يؤدي إلى صعوبة في التنفس (وذمة وعائية عصبية<br />أنزيمات الكبد مثل، أنزيمات ناقلة الأمين أو ارتفاع صبغة البليروبين الصفراوية) سيقوم طبيبك بالكشف عن هذه الأعراض عن طريق استخدام فحص الدم<br />اضطراب في الفحوصات المخبرية المتعلقة بوظيفة الكلى (ارتفاع الكرياتينين أو اليوريا في الدم). □<br />خلل في تعداد خلايا الدم والذي □ كوابيس □ اضطرابات في المزاج □ : الأعراض النادرة: تؤثر على مستخدم واحد إلى ۱۰ من ۱۰,۰۰۰ مستخدم<br />يشمل: - تعداد غير طبيعي وتفاضلي لخلايا الدم، انخفاض عدد خلايا الدم البيضاء، انخفاض عدد الصفائح الدموية. هذه الأعراض الجانبية قد تؤدي إلى<br />تقرحات المعدة وتقرحات في الجزء العلوي من الأمعاء □ خفقان □ طنين الأذن □ زيادة خطر العدوى و خطر الأعراض مثل الكدمات أو نزيف الأنف<br />حدوث نوبات ربو (لوحظت لدى الأشخاص الذين يعانون من حساسية للأسبرين أو مضادات الالتهاب غير الستيرويدية □ التهاب المريء □ الدقيقة<br />طفح القراص (شرى) □ ( تقرحات شديدة في الجلد أو تقشر الجلد (متلازمة ستيفنز جونسون أو تقشر الأنسجة المتموتة البشروية التسممي □ ( الأخرى<br />التهاب الأمعاء الغليظة (القولون). □ ( اضطرابات بصرية وتشمل: - عدم وضوح الرؤيا - التهاب الملتحمة (التهاب مقلة العين أو الجفون □<br />تفاعلات تقرحية في الجلد (تفاعلات فقاعية) و حمامى عديدة الأشكال □ : الأعراض الجانبية النادرة جداً: تؤثر على أقل من مستخدم واحد من ۱۰,۰۰۰<br />وهي تفاعل جلدي تحسسي خطير يسبب بقع حمراء أو أرجوانية اللون أوتقرحات، وقد يؤثر أيضاً على الفم والعينين وغيرها من الأسطح الرطبة في الجسم<br />فشل حاد في الكلى وخاصة لدى □ التهاب الكبد والذي قد يؤدي إلى الأعراض التالية: - اصفرار الجلد أو مقلة العين - ألم في البطن - فقدان الشهية □<br />ثقب في جدار الأمعاء. □ المرضى الذين لديهم عوامل خطر مثل أمراض القلب أو السكري أو أمراض الكلى<br />ضيق في التنفس وتفاعلات جلدية □ توهان □ ارتباك □ : أعراض جانبية تكرار حدوثها غير معروف ولا يمكن تقدير حدوثها من المعلومات المتوفرة<br />تم الإبلاغ عن حدوث فشل في القلب عند المعالجة باستخدام مضادات الالتهاب غير □ (تفاعلات تأقية) طفح جلدي ناجم عن التعرض لأشعة الشمس<br />فقدان كامل لأنواع معينة من خلايا الدم البيضاء (ندرة المحببات) وخاصة في المرضى الذين يتناولون أوكسيمال بالإضافة إلى الأدوية التي □ الستيرويدية<br />يحتمل أن تكون مثبطة أو مدمرة لمكونات نخاع العظم (أدوية سامة للنقي) وهذا قد يؤدي إلى: - حمى مفاجئة - التهاب الحلق - عدوى<br />الأعراض الجانبية الناجمة عن مضادات الالتهاب غير الستيرويدية ولكن لم تشاهد بعد تناول ميلوكسيكام: تغيرات على بنية الكلى تؤدي إلى فشل كلوي<br />وجود بروتين في □ ( موت بعض الخلايا داخل الكلى (نخر أنبوبي أو حليمي حاد □ ( حالات نادرة جداً من التهاب الكلى (التهاب الكلية الخلالي □ : حاد<br />البول (متلازمة كلوية أو بيلة بروتينية).<br />تحدث إلى طبيبك أو الصيدلي إذا حدث لك أي من هذه الأعراض، وهذا قد يشمل أي أعراض جانبية أخرى محتملة وغير مذكورة في النشرة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا ينبغي استعمال أوكسيمال بعد تاريخ انتهاء الصلاحية الموجود على □ لا يحفظ بدرجة حرارة أعلى من ۳۰ &deg;م □ يحفظ بعيداً عن متناول الأطفال □<br />العلبة وعلى شريط الدواء.<br />لا ينبغي التخلص من الأدوية من خلال مياه الصرف الصحي أو المنزلي. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد<br />هذه الاجراءات على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي ميلوكسيكام. كل قرص يحتوي على ۷٫٥ ملغم , ۱٥ ملغم على التوالي من ميلوكسيكام. □<br />المكونات الأخرى هي: لاكتوز، سلولوز بلوري مكروي، كروسبوفيدون، سيترات الصوديوم ، ستيارات المغنيزيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>من جهة واحدة و غير منقوشة من الجهة &ldquo;OM أقراص ۷٫٥ ملغم هي أقراص لونها أصفر فاتح، دائرية، مسطحة، مائلة الحواف، منقوش عليها &rdquo; 7.5 □ الأخرى. من جهة واحدة وغير منقوشة من &ldquo;OM أقراص ۱٥ ملغم هي أقراص لونها أصفر فاتح، محززة، دائرية، مسطحة، مائلة الحواف، منقوش عليها &rdquo; 15 علب تحتوي على ۱۰ أقراص أوكسيمال ۷٫٥ المحفوظة في أشرطة. □ علب تحتوي على ۳۰ أقراص أوكسيمال ۷٫٥ المحفوظة في أشرطة. □ علب تحتوي على ۱۰ أقراص أوكسيمال ۱٥ المحفوظة في أشرطة. □ علب تحتوي على ۳۰ أقراص أوكسيمال ۱٥ المحفوظة في أشرطة. □</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة الاردنية لانتاج الادوية المساهمة العامة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             أيلول ۲۰۱٥
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oximal 15 mg  Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active Ingredient:

Each tablet contains Meloxicam  15 mg

Inactive Ingredients:


Inactive ingredients(s) and amount (s) per unit dose:
NAMES OF INGREDIENTS	MG/ TABLET
Lactose direct compression 	88.2
Microcrystalline cellulose 180 m 	37.1
Crospovidone 	8.8
Sodium citrate 	28.8
Magnesium stearate 	1.8

      *For a full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oximal 15 :

Light yellow scored circular flat face beveled edge embossed with “OM 15” on one side and plain on the other side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Short-term symptomatic treatment of exacerbations of osteoarthrosis.</li><li>Long-term symptomatic treatment of rheumatoid arthritis or ankylosing spondylitis.</li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;Route of administration</strong>: Oral</p><p>The total daily amount should be taken as a single dose, with water or another liquid, during a meal.</p><p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis.</p><ul><li><strong>Exacerbations of osteoarthrosis: 7.5 mg/day (one 7.5 mg tablet). </strong></li></ul><p>If necessary, in the absence of improvement, the dose may be increased to 15 mg/day (two 7.5 mg tablets).</p><ul><li><strong>Rheumatoid arthritis, ankylosing spondylitis: 15 mg/day (two 7.5 mg tablets). </strong></li></ul><p>(see also section &#39;Special populations&#39; below)</p><p>According to the therapeutic response, the dose may be reduced to 7.5 mg/day (one 7.5 mg tablet).</p><p>Do Not Exceed The Dose Of 15 Mg/Day.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Special populations</u></strong></p><p><u>Elderly patients and patients with increased risks for adverse reaction (see section 5.2):</u></p><p>The recommended dose for long term treatment of rheumatoid arthritis and ankylosing spondylitis in elderly patients is 7.5 mg per day. Patients with increased risks for adverse reactions should start treatment with 7.5 mg per day (see section 4.4).</p><p><u>Renal impairment (see section 5.2):</u></p><p>In dialysis patients with severe renal failure, the dose should not exceed 7.5 mg per day.</p><p>No dose reduction is required in patients with mild to moderate renal impairment (i.e. patients with a creatinine clearance of greater than 25 ml/min). (For patients with non-dialysed severe renal failure, see section 4.3)</p><p><u>Hepatic impairment (see section 5.2):</u></p><p>No dose reduction is required in patients with mild to moderate hepatic impairment (For patients with severely impaired liver function, see section 4.3).</p><p><u>Children and adolescents: </u></p><p>Meloxicam7.5 mg tablets is contraindicated in children and adolescents aged under 16 years (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This medicinal product is contra-indicated in the following situations: 
•	Third trimester of pregnancy (see section 4.6 'Pregnancy and lactation'); 
•	Children and adolescents aged under 16 years; 
•	Hypersensitivity to Meloxicam or to one of the excipients or hypersensitivity to substances with a similar action, e.g. NSAIDS , aspirin. Meloxicam should not be given to patients who have developed signs of asthma, nasal polyps, angioneurotic edema or urticaria following the administration of aspirin or other NSAIDS ; 
•	History of gastrointestinal bleeding or perforation, related to previous NSAIDS  therapy; 
•	Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding); 
•	Severely impaired liver function; 
•	Non-dialysed severe renal failure; 
•	Gastrointestinal bleeding, history of cerebrovascular bleeding or other bleeding disorders; 
•	Severe heart failure

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2, and GI and cardiovascular risks below).</p><p>The recommended maximum daily dose should not be exceeded in case of insufficient therapeutic effect, nor should an additional NSAID be added to the therapy because this may increase the toxicity while therapeutic advantage has not been proven. The use of Meloxicam with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided.</p><p>Meloxicam is not appropriate for the treatment of patients requiring relief from acute pain.</p><p>In the absence of improvement after several days, the clinical benefit of the treatment should be reassessed.</p><p>Any history of oesophagitis, gastritis and/or peptic ulcer must be sought in order to ensure their total cure before starting treatment with Meloxicam. Attention should routinely be paid to the possible onset of a recurrence in patients treated with Meloxicam and with a past history of this type.</p><p><strong>Gastrointestinal effects</strong></p><p>GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious GI events.</p><p>The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (see below and 4.5).</p><p>Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.</p><p>Caution is advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as heparin as curative treatment or given in geriatrics, anticoagulants such as warfarin, or other non steroidal anti-inflammatory drugs, including acetylsalicylic acid given at anti-inflammatory doses (&ge; 1g as single intake or &ge; 3g as total daily amount) (see section 4.5).</p><p>When GI bleeding or ulceration occurs in patients receiving Meloxicam the treatment should be withdrawn.</p><p>NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn&#39;s disease) as these conditions may be exacerbated (see section 4.8 &ndash; undesirable effects).</p><p><strong>Cardiovascular and cerebrovascular effects</strong></p><p>Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.</p><p>Clinical monitoring of blood pressure for patients at risk is recommended at baseline and especially during treatment initiation with Meloxicam.</p><p>Clinical trial and epidemiological data suggest that use of some NSAIDs including Meloxicam (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for Meloxicam.</p><p>Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with Meloxicam after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).</p><p><strong>Skin reactions</strong></p><p>Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see 4.8). Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Meloxicam should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p><strong>Parameters of liver and renal function</strong></p><p>As with most NSAIDs, occasional increases in serum transaminase levels, increases in serum bilirubin or other liver function parameters, as well as increases in serum creatinine and blood urea nitrogen and other laboratory disturbances, have been reported. The majority of these instances involved transitory and slight abnormalities. Should any such abnormality prove significant or persistent, the administration of Meloxicam should be stopped and appropriate investigations undertaken.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Functional renal failure</strong></p><p>NSAIDs, by inhibiting the vasodilating effect of renal prostaglandins, may induce a functional renal failure by reduction of glomerular filtration. This adverse event is dose-dependant. At the beginning of the treatment, or after dose increase, careful monitoring of diuresis and renal function is recommended in patients with the following risk factors:</p><ol><li>Elderly</li><li>Concomitant treatments such as ACE inhibitors, angiotensin-II antagonists, sartans, diuretics (see section 4.5. Interaction with other medicinal products and other forms of interaction)</li><li>Hypovolemia (whatever the cause)</li><li>Congestive heart failure</li><li>Renal failure</li><li>Nephrotic syndrome</li><li>Lupus nephropathy</li><li>Severe hepatic dysfunction (serum albumin &lt;25 g/l or Child-Pugh score &ge;10)</li></ol><p>In rare instance NSAIDs may be the cause of interstitial nephritis, glomerulonephritis, renal medullary necrosis or nephrotic syndrome.</p><p>The dose of Meloxicam in patients with end-stage renal failure on haemodialysis should not be higher than 7.5 mg. No dose reduction is required in patients with mild or moderate renal impairment (i.e. in patients with a creatinine clearance of greater than 25 ml/min).</p><p><strong>Sodium, potassium and water retention</strong></p><p>Induction of sodium, potassium and water retention and interference with the natriuretic effects of diuretics may occur with NSAIDs. Furthermore, a decrease of the antihypertensive effect of antihypertensive drugs can occur (see section 4.5). Consequently, oedema, cardiac failure or hypertension may be precipitated or exacerbated in susceptible patients as a result. Clinical monitoring is therefore necessary for patients at risk (see sections 4.2 and 4.3).</p><p><strong>Hyperkalaemia</strong></p><p>Hyperkalaemia can be favoured by diabetes or concomitant treatment known to increase kalaemia (see section 4.5). Regular monitoring of potassium values should be performed in such cases.</p><p><strong>Other warnings and precautions</strong></p><p>Adverse reactions are often less well tolerated in elderly, fragile or weakened individuals, who therefore require careful monitoring. As with other NSAIDs, particular caution is required in the elderly, in whom renal, hepatic and cardiac functions are frequently impaired. The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2).</p><p>Meloxicam, as any other NSAID may mask symptoms of an underlying infectious disease.</p><p>The use of Meloxicam may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of Meloxicam should be considered (see section 4.6).</p><p>Meloxicam7.5 mg tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p><strong><u>Pharmacodynamic Interactions:</u></strong><strong> </strong></p><ul><li><strong>Other non steroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid <u>&gt;</u> 3g/d: </strong></li></ul><p>Combination (see section 4.4) with other non steroidal anti-inflammatory drugs, including acetylsalicylic acid given at anti-inflammatory doses (&ge; 1g as single intake or &ge; 3g as total daily amount) is not recommended.</p><ul><li><strong>Corticosteroids (e.g. Glucocorticoids):</strong></li></ul><p>The concomitant use with corticosteroids requests caution because of an increased risk of bleeding or gastrointestinal ulceration.</p><ul><li><strong>Anticoagulant or heparin administered in geriatrics or at curative doses:</strong></li></ul><p>Considerably increased risk of bleeding, via inhibition of platelet function and damage to the gastroduodenal &nbsp;mucosa. NSAIDs may enhance the effects of anti-coagulants, such as warfarin (see section 4.4). The concomitant use of NSAIDs and anticoagulants or heparin administered in geriatrics or at curative dose is not recommended (see section 4.4).</p><p>In remaining cases of heparin use caution is necessary due to an increased bleeding risk.</p><p>Careful monitoring of the International Normalized Ratio(INR) &nbsp;is required if it proves impossible to avoid such combination.</p><p>&nbsp;</p><ul><li><strong>Thrombolytics and antiplatelet drugs: </strong></li></ul><p>Increased risk of bleeding, via inhibition of platelet function and damage to the gastroduodenal mucosa.</p><ul><li><strong>Selective serotonin reuptake inhibitors (SSRIs):</strong></li></ul><p>Increased risk of gastrointestinal bleeding.</p><ul><li><strong>Diuretics, ACE inhibitors and Angiotensin-II Antagonists:</strong></li></ul><p>NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or Angiotensin-II antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter (see also section 4.4).</p><p><strong>Other antihypertensive drugs (e.g. Beta-blockers):</strong></p><p>As for the latter, a decrease of the antihypertensive effect of beta-blockers (due to inhibition of prostaglandins with vasodilatory effect) can occur.</p><ul><li><strong>Calcineurin inhibitors (e.g. cyclosporin, tacrolimus): </strong></li></ul><p>Nephrotoxicity of <em>calcineurin inhibitors </em>may be enhanced by NSAIDs via renal prostaglandin mediated effects. During combined treatment renal function is to be measured. A careful monitoring of the renal function is recommended, especially in the elderly.</p><ul><li><strong>Intrauterine devices: </strong></li></ul><p>NSAIDs have been reported to decrease the efficacy of intrauterine devices.</p><p>A decrease of the efficacy of intrauterine devices by NSAIDs has been previously reported but needs further confirmation.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Pharmacokinetic Interactions: Effect of Meloxicam on the pharmacokinetics of other drugs</u></strong></p><ul><li><strong>Lithium</strong><em>: </em></li></ul><p>NSAIDs have been reported to increase blood lithium levels (via decreased renal excretion of lithium), which may reach toxic values. The concomitant use of lithium and NSAIDs is not recommended (see section 4.4). If this combination appears necessary, lithium plasma concentrations should be monitored carefully during the initiation, adjustment and withdrawal of Meloxicam treatment.</p><ul><li><strong>Methotrexate: </strong></li></ul><p>NSAIDs can reduce the tubular secretion of methotrexate thereby increasing the plasma concentrations of methotrexate. For this reason, for patients on high dosages of methotrexate (more than 15 mg/week) the concomitant use of NSAIDs is not recommended (see section 4.4).</p><p>The risk of an interaction between NSAID preparations and methotrexate, should be considered also in patients on low dosage of methotrexate, especially in patients with impaired renal function. In case combination treatment is necessary blood cell count and the renal function should be monitored. Caution should be taken in case both NSAID and methotrexate are given within 3 days, in which case the plasma level of methotrexate may increase and cause increased toxicity.</p><p>Although the pharmacokinetics of methotrexate (15mg/week) were not relevantly affected by concomitant Meloxicam treatment, it should be considered that the haematological toxicity of methotrexate can be amplified by treatment with NSAID drugs (see above). (See section 4.8)</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Pharmacokinetic Interactions: Effect of other drugs on the pharmacokinetics of Meloxicam</u></strong></p><ul><li><strong>Cholestyramine</strong><em>: </em></li></ul><p>Cholestyramine accelerates the elimination of Meloxicam by interrupting the enterohepatic circulation so that clearance for Meloxicam increases by 50% and the half-life decreases to 13<u>+</u>3 hrs. This interaction is of clinical significance.</p><p>No clinically relevant pharmacokinetic drug-drug interactions were detected with respect to the concomitant administration of antacids, cimetidine and digoxin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong></p><p>The use of Meloxicam, as with any drug known to inhibit cyclooxygenase/prostaglandin synthesis, may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of Meloxicam should be considered.</p><p><strong>Pregnancy</strong></p><p>Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of&nbsp; a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5 %. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.</p><p>During the first and second trimester of pregnancy, Meloxicam should not be given unless clearly necessary. If Meloxicam is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.</p><p>During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose &nbsp;the foetus to:</p><p>&bull; Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension).</p><p>&bull; Renal dysfunction, which may progress to renal failure with oligo-hydroamniosis.</p><p>&nbsp;</p><p>During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the mother and the neonate, at the end of pregnancy, to:</p><p>&bull; Possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.</p><p>&bull; Inhibition of uterine contractions resulting in delayed or prolonged labour.</p><p>Consequently, Meloxicam is contraindicated during the third trimester of pregnancy.</p><p><strong>Lactation</strong></p><p>While no specific experience exists for Meloxicam, NSAIDs are known to pass into mother&#39;s milk. Administration therefore is not recommended in women who are breastfeeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific studies on the effect on the ability to drive and use machineries have been performed. However, on the basis of the pharmacodynamic profile and reported adverse drug reactions, Meloxicam is likely to have no or negligible influence on these abilities. However, when visual disturbances including blurred vision, dizziness, drowsiness, vertigo or other central nervous system disturbances occur, it is advisable to refrain from driving and operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;General Description</strong></p><p>Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).</p><p>Oedema, hypertension, and cardiac failure, have been reported in association with NSAID treatment.</p><p>The most commonly-observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn&#39;s disease (see section 4.4 - Special warnings and precautions for use) have been reported following administration. Less frequently, gastritis has been observed.</p><p>The frequencies of adverse drug reactions given below are based on corresponding occurrences of reported adverse events in 27 clinical trials with a treatment duration of at least 14 days. The information is based on clinical trials involving 15197 patients who have been treated with daily oral doses of 7.5 or 15 mg Meloxicam tablets or capsules over a period of up to one year.</p><p>Adverse drug reactions that have come to light as a result of reports received in relation to administration of the marketed product are included.</p><p>Adverse reactions have been ranked under headings of frequency using the following convention:</p><p>Very common (<u>&gt;</u>1/10); common (<u>&gt;</u>1/100 to &lt;1/10); uncommon (<u>&gt;</u>1/1,000 to &lt;1/100); rare (<u>&gt;</u>1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table of adverse reactions</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><u>Blood and lymphatic system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Blood count abnormal (including differential white cell count), leukopenia, thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Very rare cases of agranulocytosis have been reported.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Immune system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Allergic reactions other than anaphylactic or anaphylactoid reactions</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, anaphylactoid reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Psychiatric disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Mood altered, nightmares</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Confusional state, disorientation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Nervous system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dizziness, somnolence</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Eye disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Visual disturbance including vision blurred; conjunctivitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Ear and labyrinth disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Tinnitus</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Cardiac disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Palpitations</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac failure has been reported in association with NSAID treatment.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Vascular disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Blood pressure increased (see section 4.4), flushing</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Respiratory, thoracic and mediastinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Asthma in individuals allergic to aspirin or other NSAIDs</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Gastrointestinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Dyspepsia, nausea, vomiting, abdominal pain, constipation, flatulence, diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Occult or macroscopic gastrointestinal haemorrhage, stomatitis, gastritis, eructation</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Colitis, gastroduodenal ulcer, oesophagitis</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Gastrointestinal perforation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal haemorrhage, ulceration or perforation may sometimes be severe and potentially fatal, especially in elderly (see section 4.4).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Hepatobiliary disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Liver function disorder (e.g. raised transaminases or bilirubin)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Hepatitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Skin and subcutaneous tissue disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Angioedema, pruritus, rash</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Dermatitis bullous, erythema multiforme</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Photosensitivity reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Renal and urinary disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Sodium and water retention, hyperkalaemia (see section 4.4.Special warnings and special precautions for use and section 4.5.), renal function test abnormal (increased serum creatinine and/or serum urea)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Acute renal failure in particular in patients with risk factors (see section 4.4.)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>General disorders and administration site conditions</u></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Oedema including oedema of the lower limbs.</p></td></tr></tbody></table><p><strong>&nbsp;Information Characterising Individual Serious and/or Frequently Occurring Adverse Reactions</strong></p><p>Very rare cases of agranulocytosis have been reported in patients treated with Meloxicam and other potentially myelotoxic drugs (see section 4.5).</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;Adverse reactions which have not been observed yet in relation to the product, but which are generally accepted as being attributable to other compounds in the class</strong></p><p>Organic renal injury probably resulting in acute renal failure: very rare cases of interstitial nephritis, acute tubular necrosis, nephrotic syndrome, and papillary necrosis have been reported (see section 4.4)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms following acute NSAID overdose are usually limited to lethargy, drowsiness, nausea, vomiting and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Severe poisoning may result in hypertension, acute renal failure, hepatic dysfunction, respiratory depression, coma, convulsions, cardiovascular collapse and cardiac arrest. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs and may occur following an overdose.</p><p>Patients should be managed with symptomatic and supportive care following an NSAID overdose. Accelerated removal of Meloxicam by 4 g oral doses of cholestyramine given three times a day was demonstrated in a clinical trial</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong></p><table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Pharmacotherapeutic group: Non Steroidal Anti-Inflammatory agent, Oxicams</p><p>ATC code: M01AC06</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam family, with anti-inflammatory, analgesic and antipyretic properties.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The anti-inflammatory activity of meloxicam has been proven in classical models of inflammation. As with other NSAIDs, its precise mechanism of action remains unknown. However, there is at least one common mode of action shared by all NSAIDs (including Meloxicam): inhibition of the biosynthesis of prostaglandins, known inflammation mediators.</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>Meloxicam is well absorbed from the gastrointestinal tract, which is reflected by a high absolute bioavailability of about 90% following oral administration (capsule). Tablets, oral suspension and capsules were shown to be bioequivalent.</p><p>Following single dose administration of meloxicam, median maximum plasma concentrations are achieved within 2 hours for the suspension and within 5-6 hours with solid oral dosage forms (capsules and tablets).</p><p>With multiple dosing, steady state conditions were reached within 3 to 5 days. Once daily dosing leads to mean drug plasma concentrations with a relatively small peak-trough fluctuation in the range of 0.4 - 1.0 &micro;g/mL for 7.5 mg doses and 0.8 - 2.0 &micro;g/mL for 15 mg doses, respectively (C<sub>min</sub> and C<sub>max</sub> at steady state, correspondingly).</p><p>Mean maximum plasma concentrations of meloxicam at steady state are achieved within five to six hours for the tablet, capsule and the oral suspension, respectively. Extent of absorption for meloxicam following oral administration is not altered by concomitant food intake or the use of inorganic antacids.</p><p><strong><u>Distribution</u></strong></p><p>Meloxicam is very strongly bound to plasma proteins, essentially albumin (99%). Meloxicam penetrates into synovial fluid to give concentrations approximately half of those in plasma.</p><p>Volume of distribution is low, i.e. approx. 11 L after IM. or IV. administration, and shows interindividual variation in the order of 7 - 20%. The volume of distribution following administration of multiple oral doses of meloxicam (7.5 to 15 mg) is about 16 L with coefficients of variation ranging from 11 to 32%.</p><p><strong><u>Biotransformation</u></strong></p><p>Meloxicam undergoes extensive hepatic biotransformation. Four different metabolites of meloxicam were identified in urine, which are all pharmacodynamically inactive. The major metabolite, 5&#39;-carboxymeloxicam (60% of dose), is formed by oxidation of an intermediate metabolite 5&#39;- hydroxymethylmeloxicam, which is also excreted to a lesser extent (9% of dose). In vitro studies suggest that CYP 2C9 plays an important role in this metabolic pathway, with a minor contribution from the CYP 3A4 isoenzyme. The patient&#39;s peroxidase activity is probably responsible for the other two metabolites, which account for 16% and 4% of the administered dose respectively.</p><p><strong><u>Elimination </u></strong></p><p>Meloxicam is excreted predominantly in the form of metabolites and occurs to equal extents in urine and faeces. Less than 5% of the daily dose is excreted unchanged in faeces, while only traces of the parent compound are excreted in urine.</p><p>The mean elimination half-life varies between 13 and 25 hours after oral, IM. and IV. administration. Total plasma clearance amounts about 7 &ndash; 12 mL/min following single doses orally, intravenously or rectally administered.</p><p><strong><u>Linearity/non-linearity</u></strong></p><p>Meloxicam demonstrates linear pharmacokinetics in the therapeutic dose range of 7.5 mg 15 mg following per oral or intramuscular administration.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Special populations</u></strong></p><p><strong>Patients with hepatic/renal insufficiency: </strong></p><p>Neither hepatic, nor mild to moderate renal insufficiency has a substantial effect on meloxicam pharmacokinetics. Subjects with moderate renal impairment had significant higher total drug clearance. A reduced protein binding is observed in patients with terminal renal failure. In terminal renal failure, the increase in the volume of distribution may result in higher free meloxicam concentrations, and a daily dose of 7.5 mg must not be exceeded (see section 4.2).</p><p><strong>Elderly:</strong></p><p>Elderly male subjects exhibited similar mean pharmacokinetic parameters compared to those of young male subjects. Elderly female patients showed higher AUC-values and longer elimination half-lives compared to those of young subjects of both genders. Mean plasma clearance at steady state in elderly subjects was slightly lower than that reported for younger subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxicological profile of meloxicam has been found in preclinical studies to be identical to that of NSAIDs: gastrointestinal ulcers and erosions, renal papillary necrosis at high doses during chronic administration in two animal species.</p><p>Oral reproductive studies in the rat have shown a decrease of ovulations and inhibition of implantations and embryotoxic effects (increase of resorptions) at maternotoxic dose levels at 1mg/kg and higher. Studies of toxicity on reproduction in rats and rabbits did not reveal teratogenicity up to oral doses of 4 mg/kg in rats and 80 mg/kg in rabbits.</p><p>The affected dose levels exceeded the clinical dose (7.5-15 mg) by a factor of 10 to 5-fold on a mg/kg dose basis (75 kg person). Fetotoxic effects at the end of gestation, shared by all prostaglandin synthesis inhibitors, have been described. No evidence has been found of any mutagenic effect, either in vitro or in vivo. No carcinogenic risk has been found in the rat and mouse at doses far higher than those used clinically</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose direct compression</p><p>Microcrystalline cellulose180 mm</p><p>Crospovidone</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;Sodium citrate</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Two years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Oximal 15</strong> Tablets should not be stored at a temperature above 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Oximal &nbsp;</strong><strong>1</strong><strong>5&nbsp; </strong>Tablets are packed in boxes of 10 Tablets blistered in aluminium foil.</p><p><strong>Oximal&nbsp; </strong><strong>1</strong><strong>5&nbsp; </strong>Tablets are packed in boxes of 30 Tablets blistered in aluminium foil.</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of accordance with local requirements.&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Jordanian Pharmaceutical Manufacturing Co. Ltd.
PO Box 151
Um Al-Amad 16197
Jordan

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November  2012
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>